Prevalence of Malignancy in Adrenal Nodules With Heterogeneous Microscopic Fat on Chemical-Shift MRI: A Multiinstitutional Study.

BACKGROUND. Homogeneous microscopic fat within adrenal nodules on chemical-shift MRI (CS-MRI) is diagnostic of benign adrenal adenoma, but the clinical relevance of heterogeneous microscopic fat is not well established. OBJECTIVE. This study sought to determine the prevalence of malignancy in adrenal nodules with heterogeneous microscopic fat on dual-echo T1-weighted CS-MRI. METHODS. We performed a retrospective study of adult patients with adrenal nodules detected on MRI performed between August 2007 and November 2020 at seven institutions. Eligible nodules had a short-axis diameter of 10 mm or larger with heterogeneous microscopic fat (defined by an area of signal loss of < 80% on opposed-phase CS-MRI). Two radiologists from each center, blinded to reference standard results, determined the signal loss pattern (diffuse, two distinct parts, speckling pattern, central loss, or peripheral loss) within the nodules. The reference standard used was available for 283 nodules (pathology for 21 nodules, ≥ 1 year of imaging follow-up for 245, and ≥ 5 years of clinical follow-up for 17) in 282 patients (171 women and 111 men; mean age, 60 ± 12 [SD] years); 30% (86/282) patients had prior malignancy. RESULTS. The mean long-axis diameter was 18.7 ± 7.9 mm (range, 10-80 mm). No malignant nodules were found in patients without prior cancer (0/197; 95% CI, 0-1.5%). Four of the 86 patients with prior malignancy (hepatocellular carcinoma [HCC], renal cell carcinoma [RCC], lung cancer, or both colon cancer and RCC) (4.7%; 95% CI, 1.3-11.5%) had metastatic nodules. Detected patterns were diffuse heterogeneous signal loss (40% [114/283]), speckling (28% [80/283]), two distinct parts (18% [51/283]), central loss (9% [26/283]), and peripheral loss (4% [12/283]). Two metastases from HCC and RCC showed diffuse heterogeneous signal loss. Lung cancer metastasis manifested as two distinct parts, and the metastasis in the patient with both colon cancer and RCC showed peripheral signal loss. CONCLUSION. Presence of heterogeneous microscopic fat in adrenal nodules on CS-MRI indicates a high likelihood of benignancy, particularly in patients without prior cancer. This finding is also commonly benign in patients with cancer; however, caution is warranted when primary malignancies may contain fat or if the morphologic pattern of signal loss may indicate a collision tumor. CLINICAL IMPACT. In the absence of prior cancer, adrenal nodules with heterogeneous microscopic fat do not require additional imaging evaluation.

Magnetic resonance imaging characteristics of thymoma in Vietnamese patients with myasthenia gravis in relation to histopathological type and disease staging.

INTRODUCTION: Myasthenia gravis (MG) is a relatively uncommon neuromuscular disease. The thymus plays an important role in the pathogenesis of MG, with 70% of patients presenting with thymic follicular hyperplasia and 20% presenting with thymoma. This study aimed to characterize magnetic resonance (MR) images of thymomas in patients with MG, associated with various stages and types. MATERIAL AND METHODS: A prospective study was performed in 46 MG patients with thymoma, who underwent surgery between August 2014 and September 2018, in Vietnam. Differences in MR imaging (MRI) images, according to type and stage, were assessed by the χ2 test or Fisher's exact test and Student's t-test. A p-value < 0.05 was considered significant. RESULTS: The proportions of each type of thymomas found to be invasive were 28.6%, 61.1%, 66.7%, 90.9%, and 100%, for type A, AB, B1, B2, and B3 thymomas, respectively. Heterogeneous signal intensities on T1- and T2-weighted images, necrosis, and cysts were more commonly observed in high-risk thymomas than in low-risk thymomas. Non-invasive thymomas were more likely to display smooth margins than invasive thymomas (p < 0.05). Only 16.7% of invasive thymomas were detected in MR findings. CONCLUSIONS: Only a few characteristic MRI features could be used to differentiate thymomas by stage or type.

Can Texture Analysis Be Used to Distinguish Benign From Malignant Adrenal Nodules on Unenhanced CT, Contrast-Enhanced CT, or In-Phase and Opposed-Phase MRI?

OBJECTIVE: The purpose of this study is to determine whether second-order texture analysis can be used to distinguish lipid-poor adenomas from malignant adrenal nodules on unenhanced CT, contrast-enhanced CT (CECT), and chemical-shift MRI. MATERIALS AND METHODS: In this retrospective study, 23 adrenal nodules (15 lipid-poor adenomas and eight adrenal malignancies) in 20 patients (nine female patients and 11 male patients; mean age, 59 years [range, 15-80 years]) were assessed. All patients underwent unenhanced CT, CECT, and chemical-shift MRI. Twenty-one second-order texture features from the gray-level cooccurrence matrix and gray-level run-length matrix were calculated in 3D. The mean values for 21 texture features and four imaging features (lesion size, unenhanced CT attenuation, CECT attenuation, and signal intensity index) were compared using a t test. The diagnostic performance of texture analysis versus imaging features was also compared using AUC values. Multivariate logistic regression models to predict malignancy were constructed for texture analysis and imaging features. RESULTS: Lesion size, unenhanced CT attenuation, and the signal intensity index showed significant differences between benign and malignant adrenal nodules. No significant difference was seen for CECT attenuation. Eighteen of 21 CECT texture features and nine of 21 unenhanced CT texture features revealed significant differences between benign and malignant adrenal nodules. CECT texture features (mean AUC value, 0.80) performed better than CECT attenuation (mean AUC value, 0.60). Multivariate logistic regression models showed that CECT texture features, chemical-shift MRI texture features, and imaging features were predictive of malignancy. CONCLUSION: Texture analysis has a potential role in distinguishing benign from malignant adrenal nodules on CECT and may decrease the need for additional imaging studies in the workup of incidentally discovered adrenal nodules.

Chemical shift MRI can aid in the diagnosis of indeterminate skeletal lesions of the spine.

OBJECTIVES: To evaluate the role of chemical shift MRI in the characterisation of indeterminate skeletal lesions of the spine as benign or malignant. METHODS: Fifty-five patients (mean age 54.7 years) with 57 indeterminate skeletal lesions of the spine were included in this retrospective study. In addition to conventional MRI at 3 T which included at least sagittal T1WI and T2WI/STIR sequences, patients underwent chemical shift MRI. A cut-off value with a signal drop-out of 20 % was used to differentiate benign lesions from malignant lesions (signal drop-out <20 % being malignant). RESULTS: There were 45 benign lesions and 12 malignant lesions. Chemical shift imaging correctly diagnosed 33 of 45 lesions as benign and 11 of 12 lesions as malignant. In contrast, there were 12 false positive cases and 1 false negative case based on chemical shift MRI. This yielded a sensitivity of 91.7 %, a specificity of 73.3 %, a negative predictive value of 97.1 %, a positive predictive value of 47.8 % and a diagnostic accuracy of 82.5 %. CONCLUSIONS: Chemical shift MRI can aid in the characterisation of indeterminate skeletal lesions of the spine in view of its high sensitivity in diagnosing malignant lesions. Chemical shift MRI can potentially avoid biopsy in a considerable percentage of patients with benign skeletal lesions of the spine. KEY POINTS: • Differentiating benign from malignant skeletal lesions of the spine can be challenging. • Utility of chemical shift MRI in characterising indeterminate spinal lesion is unreported. • This study demonstrates sensitivity 91.7 %, specificity 73.3 %, diagnostic accuracy 82.5 % for CSI. • CSI is useful in differentiating benign from malignant skeletal spine lesions. • Biopsy can potentially be avoided in some patients with benign skeletal lesions.

Chemical shift MR imaging in the lumbar vertebra: the effect of field strength, scanner vendors and flip angles in repeatability of signal intensity index measurement.

BACKGROUND: To evaluate the reproducibility of signal intensity index (SII) measurements with MRI systems from different vendors and with different field strengths, and to test the effectiveness of flip angle. METHODS: Thirty-two healthy volunteers (mean age 35.3 ± 9.3 years) were enrolled in this ethics committee-approved study. Chemical shift MR imaging was performed on 1.5- and 3.0-T MR systems from three vendors. Two independent observers measured SII values in five lumbar segments. Inter- and intraobserver agreement was assessed using the interclass correlation coefficients (ICCs). Differences of mean SII values between different field strengths and MR vendors as well as flip angles were compared by using repeated-measures analysis of variance. Differences of mean SII values between different flip angles were also compared by using paired-sample t test. RESULTS: Inter- and intra-observer correlation coefficients showed good agreement (all ICC > 0.75) when measuring SII values at different MR systems (ICCs ranging from 0.896 to 0.983) and flip angles (ICCs ranging from 0.824 to 0.983). There were no significant differences in mean SII values measured by different MR vendors with different field strengths (all p > 0.05 ranging from 0.337 to 0.824). The differences in the mean SII between the four different flip angles were statistically significant (all p < 0.05 ranging from < 0.001 to 0.004) except the group of flip angle 50° versus 70° (p = 0.116). CONCLUSION: The SII measurement using chemical shift MR imaging may be comparable between different MR systems. Also high flip angles showed better stability to quantitate lumbar fat content.

Predictive Value of Chemical-Shift MRI in Distinguishing Clear Cell Renal Cell Carcinoma From Non-Clear Cell Renal Cell Carcinoma and Minimal-Fat Angiomyolipoma.

OBJECTIVE: The purpose of this study was to evaluate the diagnostic performance of chemical-shift MRI in the differentiation of clear cell renal cell carcinoma (RCC) from minimal-fat angiomyolipoma (AML) and non-clear cell RCC. MATERIALS AND METHODS: In this retrospective study, 97 patients with solid renal tumors without macroscopic fat and with a pathologic diagnosis of clear cell RCC (n = 40), non-clear cell RCC (n = 31), or minimal-fat AML (n = 26) who had undergone renal chemical-shift MRI were included. Size, location, morphology, and signal intensity (SI) of the tumors and the contralateral normal kidneys on T2-weighted and in-phase and opposed-phase images were recorded by readers blinded to the pathology. Percentage tumor-to-renal parenchymal SI drop (percentage SI drop) was calculated and correlated to tumor histology. The statistical analysis was done using Kruskal-Wallis, one-way ANOVA, chi-square, and Fisher exact tests. RESULTS: The percentage SI drop was significantly higher in clear cell RCC compared with non-clear cell RCC and minimal-fat AML (p < 0.001). Percentage SI drop of greater than 20% had 57.5% sensitivity, 96.5% specificity, and 92% positive predictive value (PPV); and percentage SI drop greater than 29% had 40% sensitivity and 100% specificity for diagnosis of clear cell RCC within the cohort of clear cell RCC, minimal-fat AML, and non-clear cell RCC. A significant proportion of minimal-fat AML (46.2%) displayed homogeneous low T2-weighted SI as opposed to clear cell RCC (5%) and non-clear cell RCC (29%) (p < 0.001). CONCLUSION: The percentage SI drop on chemical-shift MRI had high specificity and moderate sensitivity in predicting clear cell RCC over non-clear cell RCC and minimal-fat AML. A percentage SI drop greater than 20% in a renal mass without macroscopically visible fat has high PPV for clear cell RCC over minimal-fat AML and non-clear cell RCC. Among morphologic features, homogeneous low T2 SI favors minimal-fat AML over RCC.

The efficiency of chemical-shift MRI for the evaluation of thymoma in patients with myasthenia gravis.

Purposes: This research aimed to evaluate the efficiency of using chemical-shift magnetic resonance imaging (MRI) to differentiate thy-moma from non-thymoma in patients with myasthenia gravis (MG). Methods: A total of 137 subjects were split into thymoma and non-thymoma groups. The qualitative parameters and the chemical-shift ratio (CSR) were compared between the two groups, using the Chi-square test and the Student's t-test, respectively. Logistic regression was performed to investigate the significant factors associated with both the qualitative parameters and CSR values that can be used to predict thymoma. The discriminative capability of CSR was defined by the area under the receiver operating characteristic (ROC) curve (AUROC), which was used to compute an optimal cut-off point for thymoma distinction. Results: Although significant differences between groups were identified by univariate analyses for most of the qualitative parameters, during the multivariate logistic regression, only CSR was significant for the distinction between two groups, with an odds ratio (OR) of 9.700 [95% confidence interval (CI): 1.874-50.200, p = 0.007). The CSR values for the thymoma and non-thymoma groups were 1.020 ± 0.073 and 0.604 ± 0.126, respectively. With an optimal cut-off point defined at 0.825, the AUROC of CSR was 0.982. When applying this cut-off point, the sensitivity and specificity of chemical-shift MRI for the detection of thymoma were 100% and 97.22%, respectively. Conclusions: CSR values, calculated from chemical-shift MRI, was exceedingly valuable for distinguishing thymoma from non-thymoma in patients with MG.

Chemical-shift MRI versus washout CT for characterizing adrenal incidentalomas.

OBJECTIVE: To compare the accuracy of computed tomography (CT) and magnetic resonance imaging (MRI) in characterizing adrenal masses. MATERIALS AND METHODS: A total of 45 adrenal masses in 38 patients underwent unenhanced CT, enhanced CT, and chemical-shift MRI. Sensitivities and accuracies using the lesion attenuation values, absolute or relative percentage washout for CT, and adrenal-to-spleen ratio or signal intensity index for MRI were calculated. Follow-up or histopathology was used as standard reference. RESULTS: A total of 15 lipid-rich adenomas, 6 lipid-poor adenomas, and 24 nonadenomas were obtained. The sensitivities for adenoma on MRI versus CT were 81% and 95%, respectively. The specificities were 100%. CONCLUSION: CT is superior to MRI in characterizing adenomas.

Determination of a cutoff attenuation value on single-phase contrast-enhanced CT for characterizing adrenal nodules via chemical shift MRI.

PURPOSE: This study aims to determine the optimal cutoff attenuation value on single-phase contrast-enhanced CT (CECT) at which chemical shift MRI (CSMRI) yields sufficient accuracy to replace the standard CT adrenal protocol for the diagnosis of adrenal adenomas. METHODS: Between January 2010 and December 2014, a total of 49 patients (age: 20-81 years; 23 men and 26 women) with 60 adrenal tumors (48 adenomas and 12 non-adenomas) who underwent both CECT in portal venous phase and CSMRI were included in the study. Attenuation on portal venous phase CECT, adrenal-to-spleen chemical shift ratio (ASR), and signal-intensity index (SII) were obtained for each adrenal mass. RESULTS: Among different cutoff values on CECT (from <70 to <120 HU), the diagnostic accuracies for those lesions measuring <80 HU were the highest and most similar to dedicated adrenal CT. The sensitivities and specificities of SII were up to 96% (25/26) and 100% (7/7) for those measuring <80 HU, but reduced to 73% (16/22) and 80% (4/5) for those ≥80 HU. The overall sensitivities and specificities for diagnosing adrenal adenoma using SII vs. ASR were 85% (41/48) and 92% (11/12) vs. 71% (34/48) and 100% (12/12), respectively. CONCLUSIONS: CSMRI may replace CT adrenals in the work-up of patients with adrenal nodules below 80 HU on single-phase CECT, hence reducing radiation exposure and iodinated contrast administration. Adrenal nodules greater than 80 HU cannot be accurately diagnosed by CSMRI. CT adrenal protocol remains the appropriate investigative modality in those cases.

Chemical-shift MRI of rebound thymic hyperplasia with unusual appearance and intense (18)F-FDG uptake in adulthood: report of two cases.

Rebound thymic hyperplasia (RTH) with increased (18)F-FGD uptake at positron emission tomography (PET) computed tomography (CT) is typical of pediatric patients after chemotherapy, although it may occasionally occur in adults. At CT, RTH usually appears as a diffusely enlarged thymus with areas of fatty attenuation. We report two cases of RTH in adults detected at follow-up: both showed unusual morphology on CT and were confirmed at PET-CT as areas of strongly increased radiopharmaceutical uptake, which suggested disease recurrence. Chemical-shift magnetic resonance imaging, however, demonstrated fat infiltration within the tissue. Such finding was consistent with the diagnosis of RTH and was paramount in preventing unnecessary invasive procedures or treatments.